Great week/month/year for those involved.
For some Friday fun and for those who need a reminder of who is at the helm here:Jon Pilcher, BSc (Hons), FCA
Chief Executive Officer/Managing Director
Jon joined Neuren in August 2013 as CFO and was appointed CEO in May 2020. He has played a central role in all aspects of Neuren's R&D, commercial and corporate activities. Before joining Neuren he was a member of the leadership team at Acrux (ASX: ACR) throughout a period that included Acrux's IPO and listing on the ASX, the development and FDA approval of three novel pharmaceutical products and a transforming licensing deal with Eli Lilly in 2010. He formerly spent seven years in a series of senior financial positions in the R&D and corporate functions of international pharmaceutical groups Medeva and Celltech, which are now part of UCB. Jon is a Chartered Accountant and holds a degree in Biotechnology from the University of Reading in the UK.
Share Price, page-8122
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$22.33 |
Change
1.335(6.36%) |
Mkt cap ! $2.805B | |||
| Open | High | Low | Value | Volume |
| $21.50 | $22.40 | $21.50 | $10.35M | 472.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 23 | 851 | $22.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $22.33 | 280 | 1 |
View Market Depth
| Last trade - 15.22pm 17/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |